News

Updated Manufacturing and Importation Authorisation

February 13, 2018

Solural Pharma ApS receives an updated Manufacturing and Importation Authorisation No. 30108 by the Danish Health and Medicines Authority expanding its manufacturing capabilities from oral products to also include topical products and primary and secondary packaging of Investigational Medicinal Products.

Solural Pharma gets a European patent

August 9, 2017

The European Patent office has announced a decision to grant Solural Pharma a European patent “Solid Oral Dosage Form of Testosterone Derivative.”

Ascelia Pharma AB acquires Oncoral Pharma ApS

June 30, 2017

Ascelia Pharma AB acquires Oncoral Pharma ApS and its novel tablet based proprietary formulation of the chemotherapeutic agent, irinotecan, which today is only available as an intravenous infusion product. Solural Pharma will continue to support Ascelia Pharma with chemistry manufacturing and control services.

Solural US patent issued

June 20, 2017

The United States Patent and Trademark office has issued the Solural patent “Solid Oral Dosage Form of Testosterone Derivative”.

First human dosing in combination with oral capicitabine tablet

June 1, 2017

Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral Irinotecan tablet product developed by Solural Pharma in combination therapy with oral capicitabine tablet in adult patients with solid tumors.

Oncoral Pharma ApS gets an Innobooster grant

September 21, 2016

The Danish Innovation Fund has granted Oncoral Pharma ApS 497.310 DKK as an Innobooster grant to support an open label phase I study to show that their proprietary oral irinotecan tablet product can be taken together with oral capecitabine tablet as a new, safe and effective tablet based treatment to be taken at home.

Exclusive license agreement

June 29, 2016

Solural Pharma ApS enters into an exclusive license agreement with Dyna Therapeutics Co., Ltd, Korea to develop and commercialize SOL-804 for treatment of metastatic castration resistant prostate cancer. SOL-804 is based on the proprietary Solural Lymphatic Targeting Technology.

First human dosing initiated by Oncoral Pharma

July 16, 2015

Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral irinotecan product developed by Solural Pharma

Certificate of GMP Compliance of a Manufacturer

April 22, 2015

Solural Pharma ApS receives Certificate of GMP Compliance of a Manufacturer issued by the Danish Health and Medicines Authority 

Grant to develop a new innovative product

February 17, 2015

The Danish Innovation Fund has granted Solural Pharma 1.5 mio DKK for together with Contera Pharma ApS (part of Bukwang Pharmaceuticals Co Ltd) , Dr. Sandra Klein, the University of Greifswald and Erweka Gmbh, to develop a new innovative product for the treatment of Morning Akinesia in Parkinson Patients.  

First human dosing

December 2, 2014

Solural Pharma initiates first human dosing on the SOL-924 new product formulation developed by Solural Pharma ApS. The project is being developed in partnership with an undisclosed major US partner. 

Grant to support human testing

October 7, 2014

Herlev Hospital has received a grant from the Danish Cancer Society of 1 mio DKK  to support human testing of the Oncoral Pharma oral irinotecan product

Exclusive licensing agreement

July 17, 2014

Solural Pharma ApS enters into an exclusive licensing agreement with an undisclosed US partner on the development of a new proprietary product developed by Solural Pharma.

Oncoral Pharma ApS and Herlev Hospital receives a grant from the Advanced Technology Foundation for developing an oral treatment of an existing intravenous chemotheraphy. read more →

Solural Pharma ApS spin-out technology and together with Østjysk Innovation A/S form a new company Oncoral Pharma ApS with the purpose to develop a new tablet treatment of an existing intravenous chemotheraphy. read more →

New agreement

September 20, 2013

Solural Pharma ApS enters into a Master Service Agreement with a major US Pharmaceutical company on the development of a new oral treatment within hormone disorders. read more →

The company has moved to new and larger facilities at Energivej 42 in Ballerup, 20 km from Copenhagen. read more →

The company has signed a Letter of Intent with a partner for the development of an oral oncology product intended for metronomic dosing. read more →

First patent application

December 20, 2012

The company has filed its first patent application for a European patent. read more →

Solural Pharma ApS

October 29, 2012

Solural Pharma is formally registered at Erhvervs og Selskabsstyrelsen to become inaugurated as Solural Pharma ApS. The company was founded and will initially be managed by Ann Fullerton and Peter G Nielsen. The company has its premises at Kanalholmen 8-12, Hvidovre, Copenhagen, Denmark, where we also have access to laboratory and GMP pilot facilities. read more →